Declining metabolic health has become a public health crisis in most countries around the world. Disregarding the 7% and 10% of Canadians and Americans, respectively, that have full blown diabetes, another third of the population suffers from prediabetic conditions such as metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). This metabolic distress is a massive burden on our health care systems, and at least for Metabolic Syndrome and NAFLD, it is largely reversible.
Only improved diet and increased exercise have truly shown to combat these pre-disease states, but there is some hope. Hydrogen water has promising early clinical data on reversing these conditions. In fact, our Drink HRW tablets were shown to improve markers in a pilot study on NAFLD (12 participants randomized double blind placebo controlled crossover for 28 days), and were shown to improve 18 of 20 measured outcomes in a 60 participant randomized double blind placebo controlled trial lasting 24 weeks on metabolic syndrome! As our clinical evidence grows, hydrogen water generated by our tablets could be the next big aide in tackling this metabolic health crisis.
Metabolic Syndrome is a prediabetic state where our metabolic functions are in the stages of becoming seriously impaired. Metabolic Syndrome is rampant through the North American population, with an estimated 1 in 3 currently being afflicted by the condition. The good news is metabolic syndrome is reversible through lifestyle changes like diet and exercise- and possibly through supplementing with high-dose hydrogen water, as well. In a 60 participant, 24 week, randomized double blind placebo controlled trial a high dose of hydrogen water using 3 of our tablets per day showed to be significant in 18 of 20 measured parameters in this study. Moreover, metabolic syndrome is considered by many experts to be a different expression of the same issue that leads to NAFLD, making this study very complementary to our study on NAFLD.
Non-Alcoholic Fatty Liver Disease (NAFLD) and Hydrogen-Rich Water
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide and an effective treatment remains elusive. Since metabolic impairment plays a major role in NAFLD pathogenesis, any pharmaceuticals or supplements, such as molecular hydrogen (H2), that advance lipid and glucose metabolism could be appropriate to tackle this complex condition. While this is just a very preliminary pilot study and should NOT be taken as medical advice, it is an interesting publication showing a potential benefit of hydrogen water and specifically our tablets:
In an important secondary analysis of the study group from our NAFLD clinical trial, researchers determined that in just 28 days high dose hydrogen water from our hydrogen tablets improved insulin sensitivity by 11%.